Literature DB >> 28835324

Resection or Transplant in Early Hepatocellular Carcinoma.

Markus B Schoenberg1, Julian N Bucher, Adrian Vater, Alexandr V Bazhin, Jingcheng Hao, Markus O Guba, Martin K Angele, Jens Werner, Markus Rentsch.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) has an incidence of 5-10 per 100 000 persons per year in the Western world. In 20% of cases, surgical liver resection (LR) or liver transplantation (LT) can be performed. LT results in longer survival, as it involves resection not only of the tumor, but of pre - cancerous tissue as well. The optimal allocation of donor organs depends on the identification of patients for whom LR is adequate treatment. In this meta-analysis, we compare LT and LR for patients with early HCC and wellcompensated cirrhosis.
METHODS: A systematic review of the pertinent literature was followed by a subgroup analysis of the studies in which patients with early HCC and wellcompensated cirrhosis were followed up after either LR or LT. Overall survival at 1, 3, and 5 years, as well as morbidity and mortality, were compared in a random effects meta-analysis.
RESULTS: 54 studies with a total of 13 794 patients were included. Among patients with early HCC, the overall survival after LT became higher than the overall survival after LR 5 years after surgery (66.67% versus 60.35%, odds ratio 0.60 [0.45; 0.78], p <0.001); there was no significant difference 1 year or 3 years after surgery. Nor was there any significant difference in morbidity or mortality between the two types of treatment in this subgroup. These findings contrast with the results obtained in all of the studies, which documented significantly better survival 3 years after LT.
CONCLUSION: Three years after surgery, the survival rates and complication rates of patients with early HCC treated with either LR or LT are comparable. Resection should therefore be the preferred form of treatment if the prerequisites for it are met. In case of recurrent tumor, these patients can still be evaluated for liver transplantation. This strategy could improve the allocation of donor organs.

Entities:  

Mesh:

Year:  2017        PMID: 28835324      PMCID: PMC5624271          DOI: 10.3238/arztebl.2017.0519

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  81 in total

1.  Comparison of hepatic resection and hepatic transplantation in the treatment of hepatocellular carcinoma among cirrhotic patients.

Authors:  Mohsen Shabahang; Dido Franceschi; Noriyo Yamashiki; Raj Reddy; Peter A Pappas; Kuky Aviles; Sonia Flores; Andrea Chaparro; Joseph U Levi; Danny Sleeman; Andreas G Tzakis; Tomoaki Kato; David M Levi; Alan S Livingstone
Journal:  Ann Surg Oncol       Date:  2002-11       Impact factor: 5.344

2.  Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation.

Authors:  Carlos Margarit; Alfredo Escartín; Lluis Castells; Víctor Vargas; Elena Allende; Itxarone Bilbao
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

3.  Surgical management of hepatocellular carcinoma in Child-Pugh class B cirrhotic patients: hepatic resection and/or microwave coagulation therapy versus living donor liver transplantation.

Authors:  Noboru Harada; Ken Shirabe; Yasuharu Ikeda; Daisuke Korenaga; Kenji Takenaka; Yoshihiko Maehara
Journal:  Ann Transplant       Date:  2012-12-31       Impact factor: 1.530

4.  Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy.

Authors:  Jian-Yong Lei; Lu-Nan Yan; Wen-Tao Wang
Journal:  World J Gastroenterol       Date:  2013-07-21       Impact factor: 5.742

5.  Surgical treatment of hepatocellular carcinoma on cirrhosis: a Western experience.

Authors:  A Mazziotti; G L Grazi; A Cavallari
Journal:  Hepatogastroenterology       Date:  1998-08

6.  Short-term and long-term outcomes of surgical treatment for HCC within Milan criteria with cirrhotic portal hypertension.

Authors:  Wang Chuan; Chuan Li; Tian-fu Wen; Lv-nan Yan; Bo Li; Guan-lin Liang; Ke-wei Li
Journal:  Hepatogastroenterology       Date:  2014 Nov-Dec

Review 7.  Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment.

Authors:  Johannes Weiß; Monika Rau; Andreas Geier
Journal:  Dtsch Arztebl Int       Date:  2014-06-27       Impact factor: 5.594

Review 8.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

Authors:  Jordi Bruix; Maria Reig; Morris Sherman
Journal:  Gastroenterology       Date:  2016-01-12       Impact factor: 22.682

9.  Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies.

Authors:  Zheng Zheng; Wenhua Liang; Daniel P Milgrom; Zhouying Zheng; Paul M Schroder; Ning S Kong; Changsheng Yang; Zhiyong Guo; Xiaoshun He
Journal:  Transplantation       Date:  2014-01-27       Impact factor: 4.939

10.  Comparison of liver resection and transplantation for Child-pugh A cirrhotic patient with very early hepatocellular carcinoma and portal hypertension.

Authors:  Yan Dai; Chuan Li; Tian-Fu Wen; Lu-Nan Yan
Journal:  Pak J Med Sci       Date:  2014-09       Impact factor: 1.088

View more
  8 in total

1.  Liver Transplantation in Hepatocellular Carcinoma: Experiences from the Shiraz Transplant Center.

Authors:  A Dastyar; H Nikoupour; A Shamsaeefar; P Arasteh; A BurBur; K Kazemi; M Dehghani; S Ghazimoghaddam; A K Sanaei; H Eghlimi; S A Malekhosseini; S Nikeghbalian
Journal:  Int J Organ Transplant Med       Date:  2021

2.  Highly differential count of circulating and tumor infiltrating immune cells in patients with non-HCV/non-HBV hepatocellular carcinoma.

Authors:  Markus Bo Schoenberg; Tong Zhu; Jingcheng Hao; Julian Nikolaus Bucher; Xiaokang Li; Xinyu Li; Yongsheng Han; Dionysios Koliogiannis; Michaela Svihla; Markus Otto Guba; Jens Werner; Alexandr V Bazhin
Journal:  Cancer Immunol Immunother       Date:  2021-09-28       Impact factor: 6.630

Review 3.  [Early stage liver cancer : Hepatocellular carcinoma].

Authors:  P R Scherber; G Gäbelein; R M Eisele; D Igna; M Glanemann
Journal:  Chirurg       Date:  2018-04       Impact factor: 0.955

4.  Preoperative Liver Function Guiding HCC Resection in Normal and Cirrhotic Liver.

Authors:  Friedrich Anger; Ingo Klein; Stefan Löb; Armin Wiegering; Gurinder Singh; Dominique Sperl; Oliver Götze; Andreas Geier; Johan Friso Lock
Journal:  Visc Med       Date:  2020-06-12

5.  Perivascular Tumor-Infiltrating Leukocyte Scoring for Prognosis of Resected Hepatocellular Carcinoma Patients.

Authors:  Markus Bo Schoenberg; Jingcheng Hao; Julian Nikolaus Bucher; Rainer Christoph Miksch; Hubertus Johann Wolfgang Anger; Barbara Mayer; Julia Mayerle; Jens Neumann; Markus Otto Guba; Jens Werner; Alexandr V Bazhin
Journal:  Cancers (Basel)       Date:  2018-10-18       Impact factor: 6.639

6.  Low expression of long noncoding RNA CTC-297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma.

Authors:  Sicong Zhu; Xuelian Huang; Kelin Zhang; Wenliang Tan; Zhirong Lin; Qing He; Yajin Chen; Changzhen Shang
Journal:  Cancer Med       Date:  2019-11-01       Impact factor: 4.452

7.  Low expression of VSIG4 is associated with poor prognosis in hepatocellular carcinoma patients with hepatitis B infection.

Authors:  Sicong Zhu; Wenliang Tan; Wenxin Li; Rui Zhou; Xiaolin Wu; Xianqing Chen; Wenda Li; Changzhen Shang; Yajin Chen
Journal:  Cancer Manag Res       Date:  2018-09-20       Impact factor: 3.989

8.  A novel machine learning algorithm to predict disease free survival after resection of hepatocellular carcinoma.

Authors:  Markus Bo Schoenberg; Julian Nikolaus Bucher; Dominik Koch; Nikolaus Börner; Sebastian Hesse; Enrico Narciso De Toni; Max Seidensticker; Martin Kurt Angele; Christoph Klein; Alexandr V Bazhin; Jens Werner; Markus Otto Guba
Journal:  Ann Transl Med       Date:  2020-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.